MAPK6 and intrahepatic cholangiocarcinoma: Collectively, we propose a potential molecular mechanism in which metformin and ATO inhibit ICC development via modulation of a network involving the AMPK, p38 MAPK, ERK3, and mTORC1 pathways (Fig. 7e).